NCT01998035 - Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions

Lymphoid MalignanciesLymphomaHodgkin LymphomaNon-hodgkin Lymphoma

Interventions

DRUG

RomiDEPsin 10 MG/M2

"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10 mg/m2)"

DRUG

Oral 5-Azacitidine 100 MG

"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100 mg)"

DRUG

Romidepsin 14 MG/M2

"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (14 mg/m2)"

DRUG

Oral 5-Azacitidine 200 MG

"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (200 mg)"

DRUG

Oral 5-Azacitidine 300 MG

"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (300 mg)"

Trial Locations (1)

10019

Columbia University Medical Center, New York